SpliceBio Secures $135 Million Series B Financing to Advance Lead Program SB-007 in Stargardt Disease and Expand Pipeline of Genetic Medicines

Financing co-led by new investors EQT Life Sciences and Sanofi Ventures, with participation from Roche Venture Fund, as well as all existing investorsProceeds will support clinical development of lead program SB-007 in Stargardt disease Funding will also advance a broader pipeline of genetic medicines targeting indications in ophthalmology, neurology, and other undisclosed therapeutic areasView original content:https://www.prnewswire.co.uk/news-releases/splicebio-secures-135-million-series-b-financing-to-advance-lead-program-sb-007-in-stargardt-disease-and-expand-pipeline-of-genetic-medicines-302477917.html

@ prnewswire.co.uk

Hol dir den Wissensvorsprung der Profis. Seit 2005 liefert der Börsenbrief trading-notes verlässliche Trading-Empfehlungen – dreimal die Woche, direkt in dein Postfach. 100% kostenlos. 100% Expertenwissen. Trage einfach deine E-Mail Adresse ein und verpasse ab heute keine Top-Chance mehr.
Jetzt anmelden.